securities fraud

Lufax faces securities class action lawsuit alleging disclosure violations and fraud. Investors with losses can seek lead plaintiff status by May 20, 2026.

Class action lawsuit filed against Atara Biotherapeutics alleging false statements about manufacturing issues and regulatory prospects for tabelecleucel.

Levi & Korsinsky files securities fraud suit against Gartner ($IT) for allegedly concealing deteriorating contract value growth, citing 52% stock decline.

New Era Energy & Digital faces securities class action lawsuit alleging CEO and former CFO certified false statements about Texas data center project and undisclosed fraud scheme.

$FBRT faces securities fraud lawsuit after disclosing over-distributed capital and earnings declines, triggering 14.2% stock drop. Shareholders must file by April 27, 2026.

Boston Scientific faces securities fraud lawsuit over undisclosed EP segment weakness, triggering 17.6% stock decline and May 4 lead plaintiff deadline.

Law Offices of Howard G. Smith seeks lead plaintiffs in securities fraud cases against $CHOW, $GO, $ALIT, $IT before mid-May 2026 deadline.

Class action lawsuit filed against $SLNO for alleged misstatements about diazoxide choline safety and efficacy. Lead plaintiff deadline: May 5, 2026.

Securities fraud lawsuit targets $CHOW over alleged pump-and-dump manipulation scheme that triggered devastating 84% stock collapse in December 2025.

Law Offices of Howard G. Smith initiates securities fraud class actions against $PINS, $NUAI, $GOSS, and $MEDP; investors have until May-June 2026 deadline for lead plaintiff motions.

Atara Biotherapeutics stock collapsed 97% across two FDA rejections for tabelecleucel. Class action deadline: May 22, 2026.

Corcept Therapeutics faces class action lawsuit alleging investor deception over failed relacorilant drug trial. Stock plunged 50.4% after FDA rejection.

Class action lawsuit filed against $CHOW alleging securities fraud, market manipulation via social media misinformation, and undisclosed trading suspension risks.

Class action lawsuit filed against $ATARA alleging executives misled investors about manufacturing issues and study deficiencies affecting tabelecleucel FDA approval prospects.

Class action lawsuit filed against Gossamer Bio alleging material misstatements regarding Phase 3 PROSERA study results and hidden design flaws at Latin American test sites.

Class action lawsuit filed against Grocery Outlet ($GO) alleging securities fraud, false financial statements, and unsustainable expansion strategy from August 2025-March 2026.

Class action filed against Navan alleging IPO prospectus contained false statements regarding sales and marketing expenses needed for revenue growth.

PSIX sued for allegedly misleading investors about data center sales prospects and understating manufacturing costs. Class action covers May 2025–March 2026 purchases.

Class action lawsuit filed against monday.com alleging material misstatements on revenue expansion, growth prospects, and sales cycles from September 2025 to February 2026.

Class action lawsuit filed against $STLA alleging materially false statements on earnings forecasts and electrification strategy between February 2025 and February 2026.